Identification of a phenyl ester covalent inhibitor of caseinolytic protease and analysis of the ClpP1P2 inhibition in mycobacteria

Abstract

The caseinolytic protease complex ClpP1P2 is crucial for protein homeostasis in mycobacteria and stress response and virulence of the pathogens. Its role as a potential drug target for combating tuberculosis (TB) has just begun to be substantiated in drug discovery research. We conducted a biochemical screening targeting the ClpP1P2 using a library of compounds phenotypically active against Mycobacterium tuberculosis (Mtb). The screening identified a phenyl ester compound GDI-5755, inhibiting the growth of Mtb and M. bovis BCG, the model organism of mycobacteria. GDI-5755 covalently modified the active-site serine residue of ClpP1, rendering the peptidase inactive, which was delineated through protein mass spectrometry and kinetic analyses. GDI-5755 exerted antibacterial activity by inhibiting ClpP1P2 in the bacteria, which could be demonstrated through a minimum inhibitory concentration (MIC) shift assay with a clpP1 CRISPRi knockdown (clpP1-KD) mutant GH189. The knockdown also remarkably heightened the mutant's sensitivity to ethionamide and meropenem, but not to many other TB drugs. On the other hand, a comparative proteomic analysis of wild-type cells exposed to GDI-5755 revealed the dysregulated proteome, specifically showing changes in the expression levels of multiple TB drug targets, including EthA, Ldt_Mt2, and PanD. Subsequent evaluation confirmed the synergistic activity of GDI-5755 when combined with the TB drugs to inhibit mycobacterial growth. Our findings indicate that small-molecule inhibitors targeting ClpP1P2, when used alongside existing TB medications, could represent novel therapeutic strategies.

Keywords

caseinolytic protease / chemical–genetic interaction / drug combination / enzyme inhibitor / mycobacteria

References

[1] World Health Organization. Global tuberculosis report. 2022. https://www.who.int/teams/global-tuberculosis-programme/tb-reports

[2] Dartois VA, Rubin EJ. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat Rev Microbiol. 2022; 20: 685-701.

[3] Sauer RT, Baker TA. AAA+ proteases: ATP-fueled machines of protein destruction. Annu Rev Biochem. 2011; 80: 587-612.

[4] Sherrid AM, Rustad TR, Cangelosi GA, Sherman DR. Characterization of a Clp protease gene regulator and the reaeration response in Mycobacterium tuberculosis. PLoS One. 2010; 5: e11622.

[5] Raju RM, Unnikrishnan M, Rubin DHF, Krishnamoorthy V, Kandror O, Akopian TN, et al. Mycobacterium tuberculosis ClpP1 and ClpP2 function together in protein degradation and are required for viability in vitro and during infection. PLoS Pathog. 2012; 8: e1002511.

[6] Ollinger J, O'Malley T, Kesicki EA, Odingo J, Parish T. Validation of the essential ClpP protease in Mycobacterium tuberculosis as a novel drug target. J Bacteriol. 2012; 194: 663-668.

[7] Raju RM, Jedrychowski MP, Wei JR, Pinkham JT, Park AS, O'Brien K, et al. Post-translational regulation via Clp protease is critical for survival of Mycobacterium tuberculosis. PLoS Pathog. 2014; 10: e1003994.

[8] Lupoli TJ, Vaubourgeix J, Burns-Huang K, Gold B. Targeting the proteostasis network for mycobacterial drug discovery. ACS Infect Dis. 2018; 4: 478-498.

[9] d'Andrea FB, Poulton NC, Froom R, Tam K, Campbell EA, Rock JM. The essential M. tuberculosis Clp protease is functionally asymmetric in vivo. Sci Adv. 2022; 8: eabn7943.

[10] Bhandari V, Wong KS, Zhou JL, Mabanglo MF, Batey RA, Houry WA. The role of ClpP protease in bacterial pathogenesis and human diseases. ACS Chem Biol. 2018; 13: 1413-1425.

[11] Brötz-Oesterhelt H, Beyer D, Kroll HP, Endermann R, Ladel C, Schroeder W, et al. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat Med. 2005; 11: 1082-1087.

[12] Famulla K, Sass P, Malik I, Akopian T, Kandror O, Alber M, et al. Acyldepsipeptide antibiotics kill mycobacteria by preventing the physiological functions of the ClpP1P2 protease. Mol Microbiol. 2016; 101: 194-209.

[13] Akopian T, Kandror O, Raju RM, Unnikrishnan M, Rubin EJ, Goldberg AL. The active ClpP protease from M. tuberculosis is a complex composed of a heptameric ClpP1 and a ClpP2 ring. EMBO J. 2012; 31: 1529-1541.

[14] Akopian T, Kandror O, Tsu C, Lai JH, Wu W, Liu Y, et al. Cleavage specificity of Mycobacterium tuberculosis ClpP1P2 protease and identification of novel peptide substrates and boronate inhibitors with anti-bacterial activity. J Biol Chem. 2015; 290: 11008-11020.

[15] Moreira W, Ngan GJY, Low JL, Poulsen A, Chia BCS, Ang MJY, et al. Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteria. mBio. 2015; 6: e00253-15.

[16] Lin G, Li D, de Carvalho LPS, Deng H, Tao H, Vogt G, et al. Inhibitors selective for mycobacterial versus human proteasomes. Nature. 2009; 461: 621-626.

[17] Yang Y, Zhao N, Xu X, Zhou Y, Luo B, Zhang J, et al. Discovery and mechanistic study of novel Mycobacterium tuberculosis ClpP1P2 inhibitors. J Med Chem. 2023; 66: 16597-16614.

[18] Culp EJ, Sychantha D, Hobson C, Pawlowski AC, Prehna G, Wright GD. ClpP inhibitors are produced by a widespread family of bacterial gene clusters. Nat Microbiol. 2022; 7: 451-462.

[19] Illigmann A, Vielberg MT, Lakemeyer M, Wolf F, Dema T, Stange P, et al. Structure of Staphylococcus aureus ClpP bound to the covalent active-site inhibitor cystargolide A. Angew Chem Int Ed. 2024; 63: e202314028.

[20] Ananthan S, Faaleolea ER, Goldman RC, Hobrath JV, Kwong CD, Laughon BE, et al. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis. 2009; 89: 334-353.

[21] Maddry JA, Ananthan S, Goldman RC, Hobrath JV, Kwong CD, Maddox C, et al. Antituberculosis activity of the molecular libraries screening center network library. Tuberculosis. 2009; 89: 354-363.

[22] Goldman RC. Target discovery for new antitubercular drugs using a large dataset of growth inhibitors from PubChem. Infect Disord Drug Targets. 2020; 20: 352-366.

[23] Hackl MW, Lakemeyer M, Dahmen M, Glaser M, Pahl A, Lorenz-Baath K, et al. Phenyl esters are potent inhibitors of caseinolytic protease P and reveal a stereogenic switch for deoligomerization. J Am Chem Soc. 2015; 137: 8475-8483.

[24] Lakemeyer M, Bertosin E, Möller F, Balogh D, Strasser R, Dietz H, et al. Tailored peptide phenyl esters block ClpXP proteolysis by an unusual breakdown into a heptamer-hexamer assembly. Angew Chem Int Ed. 2019; 58: 7127-7132.

[25] Schwarz M, Hübner I, Sieber SA. Tailored phenyl esters inhibit ClpXP and attenuate Staphylococcus aureus α-Hemolysin secretion. ChemBioChem. 2022; 23: e202200253.

[26] Rock JM, Hopkins FF, Chavez A, Diallo M, Chase MR, Gerrick ER, et al. Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform. Nat Microbiol. 2017; 2: 16274.

[27] Gibson AJ, Stiens J, Passmore IJ, Faulkner V, Miculob J, Willcocks S, et al. Defining the genes required for survival of Mycobacterium bovis in the bovine host offers novel insights into the genetic basis of survival of pathogenic Mycobacteria. mBio. 2022; 13: e0067222.

[28] Sawyer J, Rhodes S, Jones GJ, Hogarth PJ, Vordermeier HM. Mycobacterium bovis and its impact on human and animal tuberculosis. J Med Microbiol. 2023; 72: 1-7.

[29] de Wet TJ, Winkler KR, Mhlanga M, Mizrahi V, Warner DF. Arrayed CRISPRi and quantitative imaging describe the morphotypic landscape of essential mycobacterial genes. eLife. 2020; 9: e60083.

[30] Gengenbacher M, Mouritsen J, Schubert OT, Aebersold R, Kaufmann SHE. Mycobacterium tuberculosis in the proteomics era. Microbiol Spectr. 2014; 2: MGM2-0020-2013.

[31] Lunge A, Gupta R, Choudhary E, Agarwal N. The unfoldase ClpC1 of Mycobacterium tuberculosis regulates the expression of a distinct subset of proteins having intrinsically disordered termini. J Biol Chem. 2020; 295: 9455-9473.

[32] Warrier T, Kapilashrami K, Argyrou A, Ioerger TR, Little D, Murphy KC, et al. N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis. Proc Natl Acad Sci USA. 2016; 113: E4523-E4530.

[33] Sartor P, Denkhaus L, Gerhardt S, Einsle O, Fetzner S. Structural basis of O-methylation of (2-heptyl-)1-hydroxyquinolin-4(1H)-one and related compounds by the heterocyclic toxin methyltransferase Rv0560c of Mycobacterium tuberculosis. J Struct Biol. 2021; 213: 107794.

[34] Commager H, Judis J. Mechanism of action of phenolic disinfectants VI. J Pharm Sci. 1965; 54: 1436-1439.

[35] Seo H, Kim S, Mahmud HA, Sultana OF, Lee Y, Yoon Y, et al. Increased susceptibility of Mycobacterium tuberculosis to ethionamide by expressing PPs-Induced Rv0560c. Antibiotics. 2022; 11: 1349.

[36] Carette X, Blondiaux N, Willery E, Hoos S, Lecat-Guillet N, Lens Z, et al. Structural activation of the transcriptional repressor EthR from Mycobacterium tuberculosis by single amino acid change mimicking natural and synthetic ligands. Nucleic Acids Res. 2012; 40: 3018-3030.

[37] Dover LG, Alahari A, Gratraud P, Gomes JM, Bhowruth V, Reynolds RC, et al. EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets. Antimicrob Agents Chemother. 2007; 51: 1055-1063.

[38] Teng Ang ML, Zainul Rahim SZ, Shui G, Dianiškova P, Madacki J, Lin W, et al. An ethA-ethR-deficient Mycobacterium bovis BCG mutant displays increased adherence to mammalian cells and greater persistence in vivo, which correlate with altered mycolic acid composition. Antimicrob Agents Chemother. 2014; 82: 1850-1859.

[39] Schuessler DL, Parish T. The promoter of Rv0560c is induced by salicylate and structurally-related compounds in Mycobacterium tuberculosis. PLoS One. 2012; 7: e34471.

[40] Zhang Y, Shi W, Zhang W, Mitchison D. Mechanisms of pyrazinamide action and resistance. Microbiol Spectr. 2013; 2: 1-12.

[41] Gopal P, Nartey W, Ragunathan P, Sarathy J, Kaya F, Yee M, et al. Pyrazinoic acid inhibits mycobacterial coenzyme A biosynthesis by binding to aspartate decarboxylase PanD. ACS Infect Dis. 2017; 3: 807-819.

[42] Sun Q, Li X, Perez LM, Shi W, Zhang Y, Sacchettini JC. The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD. Nat Commun. 2020; 11: 339.

[43] Kumar P, Arora K, Lloyd JR, Lee IY, Nair V, Fischer E, et al. Meropenem inhibits D,D-carboxypeptidase activity in Mycobacterium tuberculosis. Mol Microbiol. 2012; 86: 367-381.

[44] Kumar G, Galanis C, Batchelder HR, Townsend CA, Lamichhane G. Penicillin binding proteins and β-lactamases of Mycobacterium tuberculosis: reexamination of the historical paradigm. mSphere. 2022; 7: e0003922.

[45] Kurz SG, Wolff KA, Hazra S, Bethel CR, Hujer AM, Smith KM, et al. Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC lead to clavulanate resistance?: a biochemical rationale for the use of β-lactam-β-lactamase inhibitor combinations. Antimicrob Agents Chemother. 2013; 57: 6085-6096.

[46] Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med. 1996; 2: 662-667.

[47] Zhang L, Zhao Y, Gao Y, Wu L, Gao R, Zhang Q, et al. Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol. Science. 2020; 368: 1211-1219.

[48] Xu W, DeJesus MA, Rücker N, Engelhart CA, Wright MG, Healy C, et al. Chemical genetic interaction profiling reveals determinants of intrinsic antibiotic resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2017; 61: e01334-17.

[49] Johnson EO, Office E, Kawate T, Orzechowski M, Hung DT. Large-scale chemical-genetic strategy enables the design of antimicrobial combination chemotherapy in Mycobacteria. ACS Infect Dis. 2020; 6: 56-63.

[50] Li S, Poulton NC, Chang JS, Azadian ZA, DeJesus MA, Ruecker N, et al. CRISPRi chemical genetics and comparative genomics identify genes mediating drug potency in Mycobacterium tuberculosis. Nat Microbiol. 2022; 7: 766-779.

[51] Yan MY, Zheng D, Li SS, Ding XY, Wang CL, Guo XP, et al. Application of combined CRISPR screening for genetic and chemical-genetic interaction profiling in Mycobacterium tuberculosis. Sci Adv. 2022; 8: eadd5907.

[52] Leodolter J, Warweg J, Weber-Ban E. The Mycobacterium tuberculosis ClpP1P2 protease interacts asymmetrically with its ATPase partners ClpX and ClpC1. PLoS One. 2015; 10: e0125345.

[53] Palomino JC, Martin A, Camacho M, Guerra H, Swings J, Portaels F, et al. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2002; 46: 2720-2722.

RIGHTS & PERMISSIONS

2025 The Author(s). mLife published by John Wiley & Sons Australia, Ltd on behalf of Institute of Microbiology, Chinese Academy of Sciences.